Scancell Holdings plc (SCLP) Ord GBP0.001

Sell:9.80pBuy:11.00p0.10p (0.95%)

Prices delayed by at least 15 minutes
Sell:9.80p
Buy:11.00p
Change:0.10p (0.95%)
Deal now
Prices delayed by at least 15 minutes
Sell:9.80p
Buy:11.00p
Change:0.10p (0.95%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Scancell Holdings plc is a clinical-stage biopharmaceutical company. The Company is engaged in studying the human adaptive immune system, to generate medicines to treat unmet needs in cancer. The Company is building a pipeline of products by utilizing its four technology platforms: Moditope and ImmunoBody for vaccines and GlyMab and AvidiMab for antibodies. Its product pipeline includes Modi-1, Modi-2, SCIB1 & iSCIB1+, SCIB2, SC129, SC134, SC2811, SC27, and others. Modi-1 is the first therapeutic vaccine candidate from the Company’s Moditope platform, which targets citrullinated peptides from two different proteins which have been combined to reduce the possibility of tumor escape and have each been conjugated to a toll-like receptor (TLR) 1/2 agonist, which acts as an adjuvant. Modi-2, which targets homocitrullinated cancer antigens, is the second therapeutic vaccine candidate from the Company’s Moditope platform and has the potential to address different cancer indications to Modi-1.

Key people

Phil L'huillier
Chief Executive Officer, Executive Director
Sathijeevan Nirmalananthan
Chief Financial Officer, Executive Director
Lindy Gillian Durrant
Chief Scientific Officer, Executive Director
Callum Scott
Head of Development
Nermeen Varawalla
Chief Medical Officer
Jean-Michel Yves Sylvain Cossery
Non-Executive Chairman of the Board
Martin Diggle
Non-Executive Director
Florian N. Reinaud
Non-Executive Director
Susan Clement-Davies
Non-Executive Independent Director
Ursula M. Ney
Non-Executive Independent Director
Click to see more

Key facts

  • EPIC
    SCLP
  • Location
    United Kingdom
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    GB00B63D3314
  • Market cap
    £107.93m
  • Employees
    61
  • Shares in issue
    1.04bn
  • Exchange
    London Stock Exchange (LON)
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.